Ocriplasmin Research to
Better Inform Treatment (ORBIT)

Back to Vitreomacular Adhesion VMA

Research Title: This is a multicenter, prospective, observational, Phase 4 study that will assess clinical outcomes and safety of JETREA® administered in a real-world setting for the treatment of symptomatic vitreomacular adhesion (VMA) by assessing anatomical and functional outcomes in 1500 patients recruited across approximately 120 USA retina sites.

Sponsor: ThromboGenics

Principal Investigator: Michael Jacobson, M.D.

Description: The sites will prospectively enroll consecutive patients eligible for participation in the study. Informed consent will be obtained prior to any data being collected. This study is observational; therefore, all treatment decisions and assessments are at the discretion of the patient's treating physician and are not mandated by the study design or protocol. Patients will be enrolled at a routinely scheduled visit, on the day pf JETRA® administration after the JETREA® injection. No specific visits, examinations, laboratory tests or procedures are mandated as part of this study. There is no pre-set visit schedule, and the frequency and timing of actual patient visits is at the discretion of the treating physician following standard of care. All available and relevant data will be collected prospectively.

Start Date: April 2014

Recruitment: Completed

Project Personnel: Leslie Marcus, CCRC

Location(s): Tucker; 1462 Montreal Road West, Suite 412, Tucker, GA 30084
Northside; 1100 Johnson Ferry Rd. Bldg. 2, Suite 593, Atlanta, GA 30342
Marietta; 833 Campbell Hill Street, Suite 300, Marietta, GA 30060